Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

As of August 2022, there have been over 572 million confirmed cases of COVID-19 (9). The
pandemic has thus far claimed approximately 6.39 million lives (9). Vaccination is having a …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Inflammation is a complex pathophysiological process underlying many clinical conditions.
Platelets contribute to the thrombo‐inflammatory response. Platelet P2Y12 receptors amplify …

Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists
are associated with lower all-cause mortality in hospitalised patients with COVID-19 …

The COVID-19 pandemic has been at the forefront of medicine over the last few years.
Pregnant women are often exposed to infectious agents that can be harmful not only to the …

As of 15 April 2022, there have been over 502 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is …

In 2019, a new disease called Covid-19 was detected in Wuhan located in China which
caused seriously disease or death at any age. This disease has various symptoms such as …

what is this living guideline? Clinical question: What is the role of drugs in the treatment of
patients with COVID-19? Target audience: The target audience is clinicians and health care …